WILLIAM FRYArray
(
[0] => WP_Term Object
(
[term_id] => 49
[name] => Article and Insights
[slug] => articlesinsights
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => category
[description] =>
[parent] => 0
[count] => 5500
[filter] => raw
[cat_ID] => 49
[category_count] => 5500
[category_description] =>
[cat_name] => Article and Insights
[category_nicename] => articlesinsights
[category_parent] => 0
)
)
The COVID-19 pandemic has propelled the healthcare and life sciences industries into uncharted territory. We explore the flexibility of regulators ...
Array
(
[0] => WP_Term Object
(
[term_id] => 49
[name] => Article and Insights
[slug] => articlesinsights
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => category
[description] =>
[parent] => 0
[count] => 5500
[filter] => raw
[cat_ID] => 49
[category_count] => 5500
[category_description] =>
[cat_name] => Article and Insights
[category_nicename] => articlesinsights
[category_parent] => 0
)
)
Continuing our series of publications, in this briefing we examine the key changes to the regulatory pathway for drug-device combination products (...
Array
(
[0] => WP_Term Object
(
[term_id] => 49
[name] => Article and Insights
[slug] => articlesinsights
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => category
[description] =>
[parent] => 0
[count] => 5500
[filter] => raw
[cat_ID] => 49
[category_count] => 5500
[category_description] =>
[cat_name] => Article and Insights
[category_nicename] => articlesinsights
[category_parent] => 0
)
)
As concerns grow globally about the availability of certain drugs and equipment in the midst of the COVID-19 pandemic will we see other governments...
Array
(
[0] => WP_Term Object
(
[term_id] => 49
[name] => Article and Insights
[slug] => articlesinsights
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => category
[description] =>
[parent] => 0
[count] => 5500
[filter] => raw
[cat_ID] => 49
[category_count] => 5500
[category_description] =>
[cat_name] => Article and Insights
[category_nicename] => articlesinsights
[category_parent] => 0
)
)
Charleen O’Keeffe discusses some of the regulatory trends and challenges she sees coming down the line with Silicon Republic.
Array
(
[0] => WP_Term Object
(
[term_id] => 49
[name] => Article and Insights
[slug] => articlesinsights
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => category
[description] =>
[parent] => 0
[count] => 5500
[filter] => raw
[cat_ID] => 49
[category_count] => 5500
[category_description] =>
[cat_name] => Article and Insights
[category_nicename] => articlesinsights
[category_parent] => 0
)
)
Taking effect on 1 March 2021, the IPHA have revised their Code of Practice for the Pharmaceutical Industry